Drug intelligence / Profile preview

XLNT-3

Development stage: Preclinical
Lead developer: NAMI
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

XLNT-3 is a radiopharmaceutical candidate being developed by NAMI Therapeutics for the treatment of gastrointestinal (GI) cancers. It is part of the company's 'XLNT' series of radiopharmaceuticals, which are specifically designed to target cancers characterized by resistance and metastasis. As of early 2024, XLNT-3 is in the discovery and lead optimization stage of development. While the specific molecular target and the radioisotope used in the formulation have not been publicly disclosed, the drug is intended to provide a targeted therapeutic approach for advanced GI malignancies.

Beyond the preview

Go deeper on XLNT-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XLNT-3.

Explore the full profile